Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Name: Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO)
Brand: abinScience
SKU: HY286296
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HY286296
Реактивность видов	Human
Применения	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG
ID клона	BSI-001
Биологическая активность	BSI-001 binds strongly to BT-474 and SK-BR-3 cells with overexpressed HER2 [1]. BSI-001 (100 nM, serially diluted; 3-6 days) exerts weak inhibitory effects on the proliferation of HER2-positive cancer cells when used alone, but it exerts potent synergistic anti-proliferative effects in multiple HER2-positive cancer cell lines when combined with Trastuzumab () at a fixed dose ratio of 1:1 [1]. BSI-001 (72 h) potently inhibits the migration of BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 72 h) = induces late-stage apoptosis and PARP cleavage in BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 3 days) reduces the total HER2 protein level in BT-474 cells and inhibits HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab [1]. . In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents. Showed stronger synergism between 5G9 and trastuzumab. In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively. Apoptosis Analysis [1] Cell Line: HER2-positive human breast cancer BT-474 cells Concentration: 100 nM Incubation Time: 72 h Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.
Цель	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	P04626
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	BSI-001, BSI001, BSI001
Фон	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
Ссылки	1. Ding X, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020 Oct;60:102996. [HY286296]
Примечание	For research use only. Not suitable for clinical or therapeutic use.